Last reviewed · How we verify
NCT06898827
Distraction Therapy Using Virtual Reality in Cardiac Rehabilitation
NA trial testing IVR using the Morpheus Programme in Cardiac Disease in 20 participants. Enrolling by invitation.
30 June 2025
Quick facts
| Lead sponsor | University of Malta |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 1 September 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across Malta |
Drugs / interventions tested
- IVR using the Morpheus Programme
- Cardiac Rehabilitation control group
Conditions studied
- Cardiac Disease — all drugs for Cardiac Disease →
- Coronary Artery Bypass — all drugs for Coronary Artery Bypass →
Sponsor
University of Malta
Who can join
40 and older, any sex, with Cardiac Disease or Coronary Artery Bypass. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The European Society of Cardiology has been putting forward the need for new adjuncts or models that optimise outcomes from CR programmes. Immersive virtual reality (IVR) is one of the newest technologies whose input in CR is currently being investigated. It is a technology which helps simulate the real environment through a virtual one, allowing for interaction with the environment and to carry out exercise with variability, where intensity, repetition and feedback are key elements. It is reported that immersion in VR environments diverts the attention of the patient from unpleasant bodily sensations, thus delaying the onset of boredom and fatigue. This is reported to possibly incite higher participation. In addition, VR has some noticeable indirect benefits for postcardiac event patients. It is reported that when using head-mounted devices during stationary cycling, a reduction in sympathetic tone and thus increase blood flow to the muscles prolonging the exercise duration and enhancing fatigue resistance will result. The use of distraction therapy through VR, one which isolates the patients from the medical context and puts all the attention on the virtual experience, makes the patient be distracted from the unpleasant stimuli of the surrounding environment. Distraction therapy through VR is reported to provide positive emotions, reduce anxiety and lead to an underestimation of the treatment duration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06898827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiac Disease
Currently open trials in the same condition.
- NCT07532174 — Efferon LPS Hemoadsorption in Cardiac Surgery Patients · NA · recruiting
- NCT06294119 — Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay · NA · recruiting
- NCT07274436 — The Clinical Value of Deep Learning-Based Reconstruction Techniques in Cardiac MRI Scanning · recruiting
- NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study · NA · recruiting
- NCT05877755 — Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging · NA · recruiting
Other University of Malta trials
Trials by the same sponsor.
- NCT06774066 — High Volume Injection in Mid Portion AChilles Tendinopathy · NA · completed
- NCT05920096 — Feasibility of a Diabetes Specialist Nurse-led Smoking Cessation Intervention · NA · completed
- NCT04771936 — Relationship of Core Stability on Pain and Functional Levels in Patients Diagnosed With Hip Osteoarthritis · NA · completed
- NCT04775433 — 'The Actual and Perceived Levels of Physical Fitness and Lifestyle Habits in University of Malta Students' · unknown
- NCT04773860 — Muscle Energy Techniques in COPD Patients · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06898827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Malta
- Last refreshed: 27 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06898827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing